Transdermal drug delivery system of haloperidol to overcome self-induced extrapyramidal syndrome

Drug Development and Industrial Pharmacy

Volumn 29, Issue 4, 2003, Pages 405-415

  Samanta, M K ^a   Dube, R ^a   Suresh, B ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Extrapyramidal; Haloperidol; Self induced; Transdermal

Indexed keywords

EUDRAGIT; HALOPERIDOL; MACROGOL; NEUROLEPTIC AGENT;

ALBINISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATATONIA; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; EXTRAPYRAMIDAL SYNDROME; NONHUMAN; PSYCHIATRIC TREATMENT; RAT; STEADY STATE;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; DRUG DELIVERY SYSTEMS; FEMALE; HALF-LIFE; HALOPERIDOL; HUMANS; MICE; RABBITS; RATS; SCHIZOPHRENIA;

EID: 0038302877     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120018376     Document Type: Article

References (26)

1. Anonymous. Where next with psychiatric illness? Nature 1988, 336, 95-96.
2. Balant-Gorgia, A.E.; Balant, L. Antipsychotic drugs, clinical pharmacokinetics of potential candidates for plasma concentrations monitoring. Clin. Pharmacokinet. 1987, 13, 65-90.
3. Bhalla, H.L.; Bhate, A.S. Feasibility studies on transdermal films of ephedrine. Indian Drugs 1994, 31 (7), 328-332.
4. Crane, G.E. Tardive dyskinesia and related neurologic disorders. Handbook of Psychopharmacology; Plenum Press: New York, 1978; Vol. 10, 165-196.
5. Casey, D.E. Tardive dyskinesia (Review). West. J. Med. 1990, 153 (5), 535-541.
6. Casey, D.E. Neuroleptic drug induced extra pyramidal syndromes and tardive dyskinesia (Review). Schizophrenia Res. 1991, 4 (2), 109-120.
7. Desai, S.M.; Sahajwala, C.G.; Lalla, J.K. Chlorpromazine hydrochloride in controlled release dosage forms: derivation of a two compartment open model for determining its desired concentrations in the formulations. Indian Drugs 1990, 27 (9), 462-471.
8. Gerken, A.; Wetzel, H.; Benkert, O. Extra-pyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting test study in 22 acutely ill schizophrenic patients. Pharmacopsychiatry 1991, 24. (4), 132-137.
9. Glazer, W.M.; Kane, J.M. Depot neuroleptic therapy: an underutilized treatment option. J. Clin. Psychiatry 1992, 53, 426-433.
10. Gibbered, F.B. Management of Parkinson's disease. Br. Med. J. 1987, 294, 1393-1394.
11. Howells, J.G. The Concept of Schizophrenia: Historical Perspectives, 1st Ed.; American Psychiatric Press: Washington, 1991; 18.
12. Horiguchi, J.; Nishimatsu, O. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double blind study. Japanese J. Psychiatr. Neurol. 1992, 46 (3), 733-739.
13. Huimin, H.; Weiguo, G.; Meisen, Z.; Yazhen, W.; Lixi, S.; Songsheng, G.; Dingcai, P. Preparation and bioavailability of controlled release tablets of chlorpromazine hydrochloride. Yiyao Gongye 1988, 19 (8), 355-358.
14. Johnson, D.A.W.; Pasterski, G.; Ludlow, J.M.; Strect, K.; Taylor, R.D.W. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients; Drugs and social consequences. Acta Psychiatrica Scandinavica 1983, 67, 339-352.
15. Jenner, P.; Marsden, C.D. Adaptive changes in brain dopamine function as a result of neuroleptic treatment. Adv. Neurol. 1988, 49, 417-431.
16. Kulkarni, S.K. Handbook of Experimental Pharmacology, 2nd Ed.; Jain, M.K., Ed.; Vallabh Prakashan: Delhi, 1987; 62.
17. Klawans, H.L.; Tanner C.M.; Goetz C.G. Epidemiology and phathophysiology of tardive dyskinesia. Adv. Neurol. 1988, 49, 185-197.
18. Katsumi, M.; Takaichi, A.; Hari, O.; Tsukasa, K; Itaru, V. High performance liquid chromatography determination of haloperidol in plasma. J. Chromatogr. 1991, 223, 449-453.
19. Lalla, J.K.; Seethalakshmi, K.R.; Dattani, K.K. Nitroglycerin controlled release transdermal patch. Indian Drugs 1989, 26 (6), 284-295.
20. Misra, A.N. Transdermal drug delivery. In Controlled and Novel Drug Delivery; Jain, N.K., Ed.; CBS Publishers and Distributors: New Delhi, 1997; 100-129.
21. Malhotra, A.K.; Litman, R.E.; Pickar, D. Adverse effects of antipsychotic drugs (Review). Drug Safety 1993, 9 (6), 429-436.
22. Menon, M.K.; Dandiya, P.C. The mechanism of tranquilizing action of asarone from Acorus calamus. J. Pharm. Pharmacol. 1967, 19, 170-175.
23. Mukherjee, P.K.; Kakali, S.; Balasubramaniam, R.; Pal, M.; Saha, B.P. Studies on the psychopharmacological effects of Nelumbo nucifera Gaeotn. Rhizome extract. J. Ethnopharmacol. 1996, 54 (2,3), 63-67.
24. Pradas, T.N.; Sivakumar, M. HPLC quantification of a tricomponent psychiatric formulation containing Chlorpromazine, trifluoperazine, trihexyphenidyl. Pharmazie 1992, 47 (3), 231.
25. Vyas, S.P.; Dixit, V.K. Development and performance evaluation of controlled release osmosinosules of chlorpromazine hydrochloride. Drug Dev. Ind. Phar. 1990, 16 (15), 2325-2338.
26. William, T.; Carpenter, J.R.; Robert, W.B. Medical progress: schizophrenia. The New England Journal of Medicine 1994, 330, 681-690.